Join Growin Stock Community!

Io biotech, inc.IOBT.US Overview

US StockHealthcare
(No presentation for IOBT)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

IOBT AI Insights

IOBT Overall Performance

IOBT AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

IOBT Recent Performance

-7.82%

Io biotech, inc.

0.05%

Avg of Sector

-0.31%

S&P500

IOBT PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

IOBT Key Information

IOBT Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

IOBT Profile

IO Biotech, Inc., a clinical-stage biopharmaceutical company, develops immune-modulating cancer therapies based on the T-win technology platform. The company's lead product candidate, IO102-IO103, which is designed to target immunosuppressive proteins, such as Indoleamine 2,3-dehydrogenase (IDO), and programmed death-ligand (PD-L1) that is in phase 2 clinical trial to treat melanoma, as well as in phase 1 clinical trial to treat lung, head and neck, bladder, and melanoma cancer. It also develops IO112, a product candidate that contains a single Arginase 1-derived peptide designed to target T cells that recognize epitopes derived from Arginase 1 for the treatment of cancers. The company was incorporated in 2014 and is based in Copenhagen, Denmark.

Price of IOBT

IOBT FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

IOBT Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-1.23
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
-
PB Ratio
28.80
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-1.23
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
-
PB Ratio
28.80
Price-to-FCF
-
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%

  • When is IOBT's latest earnings report released?

    The most recent financial report for Io biotech, inc. (IOBT) covers the period of 2025Q3 and was published on 2025/09/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating IOBT's short-term business performance and financial health. For the latest updates on IOBT's earnings releases, visit this page regularly.

  • How much debt does IOBT have?

    As of the end of the reporting period, Io biotech, inc. (IOBT) had total debt of 18.12M, with a debt ratio of 0.45. Long-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.

  • How much cash does IOBT have?

    At the end of the period, Io biotech, inc. (IOBT) held Total Cash and Cash Equivalents of 30.66M, accounting for 0.77 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Is IOBT's EPS continuing to grow?

    According to the past four quarterly reports, Io biotech, inc. (IOBT)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at -0.13. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of IOBT?

    Io biotech, inc. (IOBT)'s Free Cash Flow (FCF) for the period is -18.48M, calculated as Operating Cash Flow minus Capital Expenditures, representing a rise of 11.22% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.

  • What are the PEG ratio and PE ratio of IOBT?

    The latest valuation data shows Io biotech, inc. (IOBT) has a Price-To-Earnings (PE) ratio of -0.67 and a Price/Earnings-To-Growth (PEG) ratio of 0.01. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.